Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by fredgoodwinsonon Jul 24, 2020 7:28am
177 Views
Post# 31312731

Recent selling

Recent selling

Puzzled as to the weakness of the stock right now as irrespective of NMIBC there should be strong hope value in the pre-clinical progress of TLD-1433 in NSCLC at Roswell Park and Rutherrin for GBM in Toronto. 

 

Might this have to do with the IP ownership of Sherri`s super compounds as referred to in the ann below?

 

https://web.tmxmoney.com/article.php?newsid=5063081139073863&qm_symbol=TLT

 

 

We are left guessing but the volume of selling at this low price - below the level at which warrants retained from the last raise would give a profit - is unsettling and the current silence reminiscent of the long pause in the middle of Phase 1B which we were only later told co-incided with a need to re-calibrate the treatment.

 

Shareholders deserve an update - good or bad - and it is a pathetic excuse to hide behind Covid as a reason not to provide one.

 

 

Bullboard Posts